BioSpace News Archive

Kiromic BioPharma, Inc. today announces that the U.S. Food and Drug Administration (FDA) has authorized the Company’s Investigational New Drug (IND) application to initiate a Phase 1 clinical trial to evaluate Deltacel (KB-GDT-01) for patients with non-small cell lung cancer (NSCLC).

Pulse Biosciences, Inc. today announced that it has entered into a stock purchase agreement with Robert W. Duggan, an experienced life sciences executive and the Company’s Executive Chairman, for the purchase of 10,022,937 shares of the Company’s common stock.

NANO-X IMAGING LTD, an innovative medical imaging technology company, announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2022 with the U.S. Securities and Exchange Commission on May 1, 2023.

Biomea Fusion, Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application to begin a Phase I trial (COVALENT-103) of BMF-500.

Kintara Therapeutics, Inc. today announced that its President and CEO, Robert E. Hoffman, will present a corporate overview at the Aegis Capital Virtual Conference being held on May 2 – 4, 2023.

NANO-X IMAGING LTD (“Nanox” or the “Company,” Nasdaq: NNOX), an innovative medical imaging technology company, today announced that it has received a 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market the multi-source Nanox.ARC, including the Nanox.CLOUD, its accompanying cloud-based infrastructure.

Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced the appointment of Ariella Kelman, MD, as Chief Medical Officer.

Jumpcode Genomics today announced the results of a new study demonstrating the potential of Jumpcode Genomics depletion technology for improving future large-scale infectious disease testing and pandemic response.

Arima Genomics, Inc., a company leveraging 3D genomics to reveal actionable insights that will empower researchers and clinicians to improve human health, today announced the appointment of Gabrielle ‘Gabi’ Raia to the newly created position of Senior Vice President of Discovery and Clinical Sales.

Avadel Pharmaceuticals plc (Nasdaq: AVDL) announced today that the U.S. Food & Drug Administration (FDA) has granted final approval to LUMRYZ, an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy.